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Mild cognitive impairment (MCI) refers to the clinical state between normal cognition and probable Alzheimer’s disease (AD), but
persons diagnosed with MCI may progress to non-AD forms of dementia, remain MCI until death, or recover to normal cognition.
Risk factors for these various clinical changes, which we term “transitions,” may provide targets for therapeutic interventions.
Therefore, it is useful to develop new approaches to assess risk factors for these transitions. Markov models have been used to
investigate the transient nature of MCI represented by amnestic single-domain and mixed MCI states, where mixed MCI comprised
all other MCI subtypes based on cognitive assessments. The purpose of this study is to expand this risk model by including a
clinically determined MCI state as an outcome. Analyses show that several common risk factors play different roles in affecting
transitions to MCI and dementia. Notably, APOE-4 increases the risk of transition to clinical MCI but does not affect the risk for
a final transition to dementia, and baseline hypertension decreases the risk of transition to dementia from clinical MCI.
1. Introduction
Mild cognitive impairment (MCI) often refers to the clin-
ical condition between normal cognition and probable
Alzheimer’s disease (AD). However, persons diagnosed with
MCI may progress to non-AD forms of dementia, remain
MCI until death, and in some instances recover to a normal
cognitive state [1–3]. There has been considerable effort to
refine diagnostic criteria, separate MCI into amnestic and
nonamnestic subtypes, and identify the underlying etiologies
of MCI [1, 4, 5]. However, whether MCI is a true precursor
to dementia remains controversial [6–9] despite evidence of
AD neuropathology in amnestic MCI [10, 11]. This is due in
part to the description of “back transitions” (i.e., recovery to
normal cognition) that have been reported in longitudinal
studies [3, 9, 12, 13]. Although the long-term prognosis
for such cases is unclear, patients with a Clinical Dementia
Rating (CDR) global score of 0.5 often have AD pathology at
autopsy regardless of back transitions to CDR global scores
of 0 [14]. Back transitions are likely heterogeneous in origin
and may be explained by misclassification of either the MCI
or normal state, interclinician differences in application of
diagnostic criteria, within-patient variability due to medical
illness or psychosocial factors, or resistance to cognitive
decline due to cognitive reserve [15–18].
In a previous study we investigated MCI as defined by
cognitive test performance alone. Here, we have added a
clinical consensus-based MCI state as defined by the Second
International Working Group on MCI [1] and opera-
tionalized by the National Alzheimer’s Coordinating Center
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(NACC) and the Alzheimer’s Disease Neuroimaging Ini-
tiative (ADNI) [19, 20]. We now have sufficient data on
this MCI state to assess it as risk factor for dementia. The
purpose of this study is to describe our statistical model
of longitudinal data in the context of studying MCI risks
and to update our prior research with additional cognitive
assessments and clinical diagnoses from a large longitudinal
sample. Over 54% of the sample subjects now have a
terminating event (i.e., we have 35 additional dementias and
69 additional deaths) compared to the 36% in the previous
study. These additional events provide increased power to
detect potential risks for transition including age, gender,
education, APOE-4, family history of dementing illness, and
baseline hypertension.
2. Methods
2.1. Subjects. Subjects in the current study are from the Bio-
logically Resilient Adults in Neurological Studies (BRAiNS)
at the University of Kentucky’s Alzheimer’s Disease Center
(UK ADC), a longitudinal cohort of 1,030 individuals with
ongoing recruitment established in 1989 [21]. Participants
consent to extensive annual cognitive and clinical exami-
nations as well as brain donation upon death. Exclusion
criteria include age less than 60 years, active infectious dis-
eases, neurological disorders, psychiatric disorders, disabling
medical disorders, and dementing illness. Subjects included
in the current study (n = 554) comprise those included
in the previous report [22]. All subjects were cognitively
intact at study entry. All research activities were approved by
the University of Kentucky Institutional Review Board. Each
participant gave written informed consent.
2.2. Cognitive Assessments. Annual cognitive test-based as-
sessments taken on a cohort of initially cognitively normal
subjects participating in the BRAiNS project are used to
classify subjects into one of three states: normal, test-
based amnestic MCI (aMCITB), or test-based mixed MCI
(mMCITB) (Table 1). Classification of aMCITB and mMCITB
has been described previously [22, 23]. Briefly, a classifi-
cation of aMCITB results from a poor score (as defined
below) on at least one measure of episodic memory measure
(Table 1). A classification of mMCITB requires a poor score
on at least one measure of language or executive function
(Table 1) regardless of the aMCITB classification status. A
poor score is defined as at least 1.5 standard deviations (SD)
below the age-adjusted mean, which is consistent with the
Second International Working Group on MCI criteria [1];
normative values were derived from the baseline evaluations
of the entire normal cohort.
Classification into clinical consensus-based MCI
(MCICC) results from a diagnosis of MCI, which is deter-
mined according to the consensus guidelines on MCI devel-
oped by the Second International Working Group on MCI
[1]. A diagnosis of MCI requires
(1) a cognitive complaint by the subject or informant,
or evidence for longitudinal decline on cognitive test
performance (at least 1.5 SD decline);
(2) generally intact global cognition;
(3) no or minimal functional impairment;
(4) not demented by DSM-IV criteria.
Additionally, MCICC is restricted to those individuals
for whom a neurodegenerative etiology is suspected. The
NACC diagnostic criteria designate patients with cognitive
impairments but without a presumed degenerative etiol-
ogy as “cognitive impairment, not MCI” [19]. Diagnosis
of MCICC is based on a consensus team review by the
examining physician, neuropsychologist, and the clinical
research assistant administering the protocol [13]. This
MCICC designation is equivalent in most respects to the
new “MCI-Core Clinical Criteria” as defined by the National
Institute on Aging-Alzheimer’s Association Workgroup on
Diagnostic Guidelines for Alzheimer’s Disease [24]. The
primary difference is that the new criteria allow the cognitive
complaint in number one above to come from a skilled
clinician rather than only the patient or informant. A
dementia classification also results from a clinical consensus
diagnosis of dementia (most often AD), which may be based
on the dementia criteria of Diagnostic and Statistical Manual
of Mental Disorders Fourth Edition (DSM-IV) [25], criteria
of the Joint Working Group of the National Institute of the
Neurologic and Communication Disorders and Stroke-AD
and Related Disorders (NINCDS-ADRDA) [26], NINDS-
AIREN criteria for vascular dementia [27], and the 2005
Dementia with Lewy bodies (DLB) Consortium revised
criteria [28]. A diagnosis of MCICC or dementia supersedes
a classification of normal cognition, aMCITB or mMCITB in
our model.
Between their annual assessments, subjects may die or
become demented, and these states are treated as completely
absorbing competing states. MCICC is treated as a quasi-
absorbing state, as subjects do not move backward to a
transient state (i.e., normal cognition, aMCITB, or mMCITB),
but they may become demented or die.
For 19 subjects, review of the longitudinal record
revealed apparent back transitions from MCICC to normal:
nine subjects were diagnosed with MCICC, reverted to
normal, and then reconverted to MCICC, three of whom
eventually became demented; six subjects had a single
diagnosis of MCICC between several diagnoses of normal
cognition on either side; and four subjects had a single
diagnosis of MCICC at their initial evaluation following the
UK ADC’s implementation of the NACC Uniform Data Set
(UDS) cognitive and clinical testing protocol [19, 29] with
all subsequent evaluations classified as normal. Review of
each subject’s complete study history revealed in all cases that
the apparent back transitions were the result of underlying
medical conditions, conflicting data from informants, or
misclassification. Given that there are differences in the
medical comorbidities (e.g., hypothyroidism, B12 deficiency)
that can mimic MCICC in both research and general clinic
settings (cf., [13]), “treatable” cases of MCICC were not con-
sidered to reflect neurodegenerative conditions. Similarly, a
single diagnosis of “normal” in the midst of many years of
MCICC diagnoses appears to reflect a temporary resolution
of a neurodegenerative condition and so strains credulity.
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Table 1: Criteria for state classification.
State Definition
Normal cognition
No cognitive test score more than 1.5 standard deviations (SD) below the age-adjusted
mean; absence of MCICC or Dementia (see below)
Test-based amnestic
MCI (aMCITB)
At least one score more than 1.5 SD below the age-adjusted mean on the following
measures of episodic memory: Wechsler Logical Memory, Benton Visual Retention Test
(number correct or number of errors), a word list (Consortium to Establish a Registry
in Alzheimer’s Disease word list or California Verbal Learning Test ) total learning score,
delayed recall score, savings score, and the maximum recalled minus delayed recall score
Test-based mixed
MCI (mMCITB)
At least one score more than 1.5 SD below the age-adjusted mean on the following
measures of language and executive function: phonemic or category verbal fluency, Boston
Naming Test (15-item), and Trail Making Tests A or B
Clinical
consensus-based MCI
(MCICC)
A cognitive complaint by the subject or informant, or evidence for longitudinal decline on
cognitive test performance (at least 1.5 SD decline); generally intact global cognition; no
or minimal functional impairment; not demented by DSM-IV criteria; neurodegenerative
etiology suspected
Dementia
Meeting DSM-IV criteria for dementia, or NINCDS/ARDRA criteria for possible or
probable AD, or NINDS-AIREN criteria for possible or probable vascular dementia, or
DLB Consortium criteria for Lewy body disease
Normal 
cognition
Amnestic 
Clinical 
consensus  
MCI
Dementia
MCITB
Mixed 
MCITB
Death
Figure 1: Flow diagram of transitions possible between subject visits. Normal cognition is the base state for transitions made from normal
cognition, test-based amnestic MCI, and test-based mixed MCI; clinical consensus MCI is the base state otherwise.
Therefore, in light of the available evidence, the six normal
to MCICC to normal cases and the four MCICC to normal
cases were reclassified as never having MCICC, though they
still might be classified aMCITB or mMCITB, and the nine
MCICC to normal to MCICC were reclassified as MCICC at
every assessment after the first diagnosis of MCICC.
2.3. Statistical Analysis. The conditional distribution of the
cognitive status at any assessment given the status at the
prior assessment is assumed to have the Markov property.
That is, the status at the current assessment depends only
on the status at the prior assessment [30] and possibly
other risk factors. A multistate Markov chain with three
transient states (normal cognition, aMCITB, and mMCITB),
one quasi-absorbing state (MCICC), and two absorbing states
(death and dementia) was used to model the probability of
maintaining the current state or moving to a different state at
the next assessment (Figure 1). The Markov chain models the
log-odds of transition between any two temporally adjacent
assessments, here called the “prior state” and the “current
state”, versus remaining in or returning to a “base state” with
a series of four random effects polytomous logistic regression
models (i.e., one model for each transient state and one
model for the quasi-absorbing state, MCICC).
The base state is normal cognition while a participant’s
prior state is normal cognition, aMCITB, or mMCITB; once
a participant has moved into MCICC, the base state then
becomes MCICC. The model is additive, which means
in practice that although we assume the risk factors are
independent of the prior state (i.e., the effect of sex, e.g., is the
same whether the prior state is normal cognition, aMCITB,
or mMCITB; there is no interaction between the covariates
and the prior state), the estimated risk factor beta coefficients
may depend on the base state. That is, the effect of sex, for
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example, may vary with respect to a base state of normal
cognition versus a base state of MCICC. To account for
within-subject correlations, a normally distributed shared
random effect due to Salazar et al. [31] was included in the
model using PROC NLMIXED in SAS 9.2 (SAS Institute
Inc, Cary, NC). The Quasi-Newton method is used to
maximize the likelihood function, which due to the presence
of the shared random effect is an integral approximated
by an adaptive Gaussian quadrature with one quadrature
point [32, 33]. Transitions to MCICC and dementia states
are assumed to have occurred on the date of assessment
as modeling assumptions do not permit the inclusion of
interval censoring-type approaches. The model ignores any
transitions among the transient states between regularly
scheduled assessments. Statistical significance was set at α =
0.05.
2.4. Covariates. Covariates of interest include age at assess-
ment (centered at 78, the sample median), sex (1 = female,
0 = male), education (two levels: ≤12 years, >12 years),
presence (1) or absence (0) of any copies of the APOE-
4 allele, presence (1) or absence (0) of family history of
dementing illness among first degree relatives, and presence
(1) or absence (0) of hypertension at study entry. Hyperten-
sion status at entry was derived from participant responses
to the question “have you ever been told by a doctor or nurse
that you have high blood pressure?” Use of medications was
also recorded; however, reported use of an antihypertensive
medication did not supersede a participant’s response of
“no” since anti-hypertensives are used to treat other illnesses.
Also included as covariates (when the base state is normal
cognition) are two indicator variables for (1 = yes, 0 = no)
aMCITB and mMCITB; normal cognition is the reference
category. Race was not included as a covariate because almost
all of the included subjects (99%) are Caucasian.
3. Results
Study participants contribute an average of 10.8 annual
assessments (median = 10 assessments, mode = 10 assess-
ments) with the average time between assessments at approx-
imately 13 months (Table 2). Approximately 87% of subjects
who reported hypertension at baseline also reported taking
at least one anti-hypertensive medication, whereas 15% of
those who reported no history of hypertension reported
taking at least one anti-hypertensive medication.
3.1. One-Step Transitions. Table 3 enumerates the one-step
transitions associated with each arrow in Figure 1. The
majority of transitions from aMCITB, which requires a poor
score on a test of episodic memory, are back to normal
cognition at the next visit (59.3%), and only 4.4% are
transitions to MCICC or dementia. Mixed MCI (mMCITB),
which requires a poor score on a test of executive function or
language, appears more predictive of underlying impairment
with 43.8% remaining mMCITB and 7.1% transitioning to
MCICC or dementia at the next visit. Entry into MCICC
is a clear risk factor for transition to dementia since the
Table 2: Subject characteristics (n = 554).
Characteristic Summary
Age at entry, y (mean ± SD) 72.7± 7.8
Female, % 64.3
Family history of dementia, % 41.3
At least one APOE-4 allele, % 30.0
>12 years of education, % 88.1
History of hypertension at entry, % 36.6
Hypertension treated with medication, % 86.5
Number of assessments (mean ± SD) 10.8± 4.5
Time between assessments, y (mean ± SD) 1.1± 0.4
majority of the transitions into the dementia state come
from MCICC when compared to transitions into dementia
from the other states. As previously stated, recovery from
MCICC does not occur. We note that 13 of the 16 subjects
who were MCICC and died without a dementia diagnosis
have been autopsied. Of these, five had AD-type pathology
insufficient for an AD diagnosis, two had mixed AD and
vascular pathology, two had mixed vascular pathology (one
with Lewy bodies and one with hippocampal sclerosis), two
had hippocampal sclerosis, one had Parkinson’s disease, and
one had no histopathologic substrate for dementia (see also
Reference [34]).
3.2. Risk Factors. A number of risk factors alter the prob-
ability of transition to an MCI state (Table 4). Older age
increases the risk of movement into aMCITB (P = 0.0006)
and mMCITB (P < 0.0001). In addition, 12 (or fewer years)
of education predicts transition to mMCITB (P = 0.0001) but
not aMCITB. Family history of dementia “protects” against
transitions to mMCITB (P = 0.011), and female sex is
protective against entry into aMCITB (P = 0.013). Classi-
fication as mMCITB at the prior assessment is predictive of
remaining mMCITB rather than returning to normal at the
next assessment (P < 0.0001).
Demographic risk factors for transition to the MCICC
state (versus remaining in or returning to a normal state) are
older age (P < 0.0001), presence of at least one APOE-4 allele
(P = 0.0053), and high school education (12 years) or less
(P = 0.007). Classification as either aMCITB or mMCITB at
the prior assessment also increases the risk of transition to
MCICC (P = 0.0041 for aMCITB, P < 0.0001 for mMCITB).
In the absence of MCICC, risk factors for dementia
include older age (P < 0.0001) and the presence of at least
one APOE-4 allele (P = 0.0057) (Table 4). A classification
as mMCITB (P < 0.0001) but not aMCITB at the prior
assessment also increases the risk of transition to dementia
at the next visit. Risk factors for transition to death without
dementia include older age (P < 0.0001) and self-reported
hypertension at study entry (P = 0.018).
Participants in this sample who transitioned from MCICC
to dementia (n = 34) did so in an average of 2.5 ± 1.5
years (median = 2.2 years), and those who transitioned from
MCICC to death without an intervening dementia (n = 16)
did so in an average of 2.7 ± 1.7 years (median = 3.4 years).
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Table 3: One-step transition matrix (number of assessments [% of prior visit state]).
Prior visit
Current visit
Normal Amnestic MCITB Mixed MCITB Clinical Consensus MCI Dementia Death
Normal 2192 (68.3) 478 (14.9) 385 (12.0) 34 (1.1) 19 (0.6) 100 (3.1)
Amnestic MCITB 448 (59.3) 148 (19.6) 108 (14.3) 23 (3.1) 10 (1.3) 18 (2.4)
Mixed MCITB 341 (33.0) 88 (8.5) 453 (43.8) 47 (4.5) 27 (2.6) 79 (7.6)
Clinical Consensus MCI 101 (66.9) 34 (22.5) 16 (10.6)
Table 4: Estimated relative risks and 95% confidence intervals for one-step transitions to test-based amnestic MCI (aMCITB), test-
based mixed MCI (mMCITB), or clinical consensus MCI (MCICC) versus the base state of normal cognition (bolding denotes statistical
significance).
Risk factor∗ aMCITB versus Normal mMCITB versus Normal MCICC versus Normal
Age 1.02 (1.01–1.04) 1.07 (1.05–1.08) 1.12 (1.09–1.15)
Female sex (versus male) 0.77 (0.62–0.95) 1.01 (0.82–1.24) 0.71 (0.46–1.09)
Family history of dementia (yes versus no) 0.81 (0.65–1.00) 0.76 (0.62–0.94) 1.04 (0.66–1.64)
≥one APOE-4 allele (versus none) 1.04 (0.83–1.31) 1.12 (0.89–1.40) 1.89 (1.21–2.95)
≤12 years of education (versus >12 years) 1.24 (0.89–1.74) 1.79 (1.33–2.42) 2.20 (1.24–3.91)
History of hypertension (yes versus no) 0.95 (0.76–1.18) 1.04 (0.84–1.28) 0.79 (0.42–1.49)
aMCITB at prior assessment (versus normal) 1.15 (0.91–1.45) 1.00 (0.77–1.29) 2.28 (1.30–4.00)
mMCITB at prior assessment (versus normal) 0.76 (0.57–1.02) 4.51 (3.63–5.61) 4.80 (2.94–7.81)
∗
As risk factors do not depend on the prior state, covariate effects are the same regardless of whether transitions occur from a prior state of normal cognition,
aMCITB, or mMCITB.
Those cases that remain in the MCICC state (n = 50) have
carried the diagnosis for an average of 4.1± 2.4 years (medi-
an = 4.2 years). Once a transition to MCICC has occurred,
only history of hypertension at study entry appears to
influence further transitions to dementia, or death without
dementia, versus remaining in the MCICC state (Table 5).
A participant who reported baseline hypertension is more
likely to remain MCICC (P = 0.037) than to convert to de-
mentia at the next visit: the yearly transition rate to dementia
for those with hypertension at baseline is approximately
4.2% and 12.6% for those without hypertension at baseline.
4. Discussion
The addition of the MCICC state to the multistate Markov
chain confirms the utility of cognitive testing in pre-
dicting true underlying cognitive impairment. Entry into
aMCITB and particularly mMCITB, both of which are deter-
mined solely by poor performance on cognitive assessment,
increases the risk of a diagnosis of MCICC at the next
visit versus returning to normal. These results highlight
the importance of objective criteria in MCI diagnosis
and emphasize the role of cognitive testing, particularly
of language and executive function, in early detection.
Notably, poor performance limited to tests of episodic
memory (aMCITB) in this population can resolve to normal
performance at the next annual assessment as much as 60%
of the time and progress to MCICC just 3% of the time
(Table 3). Poor performance on tests of language and exec-
utive function is somewhat more stable, returning to normal
performance at the next annual assessment 33% of the time.
While there is no question that MCITB predicts MCICC, these
findings emphasize that clinicians who primarily rely on
cognitive testing should obtain longitudinal followup before
a diagnosis of MCI is given to the patient [35].
These findings reflect a novel analysis of risk factors for
MCI and dementia based on the current NACC UDS criteria
that are used across AD centers in the United States [19]
and so represent a standardized diagnostic system in contrast
to earlier analyses of MCI risk factors [36, 37]. Further, the
comparison of two different sets of MCI criteria (MCICC
versus MCITB) provides differing risk factors that could be
of clinical use in patient care. This is best highlighted in our
group’s earlier comparison of patients diagnosed with MCI
in a clinical research (i.e., the UK ADC BRAiNS cohort) as
well as a memory clinic setting where only 9% of patients
in the memory clinic had nonneurodegenerative causes for
cognitive decline in contrast to 31% of the research clinic
cases [13].
Risk factors for one-step transitions into MCICC include
age, low education, prior classification as either aMCITB or
mMCITB, and the presence of at least one APOE-4 allele.
APOE-4 is a known risk factor for AD, and although results
for MCI have been mixed, a recent study of a nationally
representative sample reported that APOE-4 was a reliable
predictor of MCI versus normal cognition [38], and data
from the Religious Orders Study reveal a 1.4-fold increased
risk of MCI in persons with an APOE-4 allele [39].
It is clear that once an individual has transitioned to
MCICC, the risk of dementia increases dramatically. In this
sample, 38.5% of individuals with MCICC have transitioned
to dementia (at an estimated overall rate of 12.6% per year)
compared to 11.8% of individuals with no history of MCICC
(at an estimated overall rate of 0.16% per year). However,
common risk factors for dementia (i.e., age, sex, education,
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Table 5: Estimated relative risks and 95% confidence intervals for one-step transitions to dementia or death without dementia versus the
base state of normal cognition or clinical consensus MCI (MCICC) (bolding denotes statistical significance).
Risk factors∗ (normal is base state; no history of MCICC) Dementia versus normal Death versus normal
Age 1.19 (1.14–1.24) 1.18 (1.15–1.21)
Female sex (versus male) 1.87 (0.95–3.68) 0.68 (0.49–0.95)
Family history of dementia (yes versus no) 1.66 (0.92–3.01) 0.82 (0.57–1.17)
≥one APOE-4 allele (versus none) 2.33 (1.28–4.23) 0.97 (0.67 –1.42)
≤12 years of education (versus >12 years) 0.75 (0.26–2.18) 1.33 (0.80 –.22)
History of hypertension (yes versus no) 0.79 (0.42–1.49) 1.49 (1.07–2.08)
aMCITB at prior assessment (versus normal) 1.85 (0.82–4.21) 0.64 (0.38–1.08)
mMCITB at prior assessment (versus normal) 4.90 (2.58–9.30) 2.67 (1.88–3.79)
Risk factors (MCICCis base state) Dementia versus MCICC Death versus MCICC
Age 1.05 (0.98–1.13) 1.03 (0.94–1.13)
Female sex (versus male) 1.75 (0.67–4.56) 1.15 (0.65–3.76)
Family history of dementia (yes versus no) 2.88 (0.95–8.72) 0.68 (0.15–3.03)
≥one APOE-4 allele (versus none) 0.69 (0.22–2.16) 2.33 (0.61–8.90)
≤12 years of education (versus >12 years) 0.97 (0.27–3.46) 0.55 (0.10–2.99)
History of hypertension (yes versus no) 0.30 (0.10–0.93) 0.70 (0.20–2.47)
∗
As risk factors depend only on the base state, covariate effects in the top half of the table are the same whether transitions occur from a prior state of normal
cognition, aMCITB, or mMCITB.
family history, and APOE-4) do not predict whether an
individual will remain in MCICC or transition to dementia,
or death without dementia, at the next visit. Similar results
have been reported in studies that have examined risk factors
for progression of cognitive impairment. Tschanz et al. [40]
noted in the Cache County cohort that while female sex and
age at onset were predictive of decline in Mini-Mental Status
Exam (MMSE) scores, education was not related to rate of
MMSE decline, and APOE-4 was related to earlier onset of
impairment but not rate of MMSE decline. Fleisher et al.
[41] reported that although APOE-4 did predict conversion
from amnestic MCI to AD over a 36-month interval, it did
not improve the predictive accuracy of their model (which
included only neuropsychological test scores).
Participants who reported hypertension at baseline were
significantly less likely to transition from MCICC to dementia
at the next visit, which may indicate a primarily vascular
rather than an AD or mixed AD and vascular etiology for
MCICC in these patients. Several studies have shown that
brain white matter changes are associated with cognitive
decline in aging [42, 43] and that vascular changes exacerbate
the cognitive decline associated with AD [44, 45]. Hoffman
and colleagues [46] reported that autopsied subjects who
took anti-hypertensive medications had significantly less
Alzheimer-type pathology than either those with no history
of hypertension or those with hypertension not treated by
medication. However, the differences in risks for treated and
untreated hypertension could not be assessed here due to
the small number of cases of untreated hypertension in the
sample.
As with aMCITB, mMCITB, and MCICC, older age in-
creases the probability of a transition to a dementia state.
Baseline hypertension plays no role in transitions to aMCITB,
mMCITB, MCICC, or dementia (in the absence of MCICC),
predicting only transitions to death (modeled as a competing
risk for dementia). This result agrees with our previous
research [23] even after four additional years of followup, as
well as with the results of a recent meta-analysis, which found
no increased risk of incidence of AD for either persons with
hypertension or those taking anti-hypertensive medications
[47]. We note that hypertension is a time-dependent risk
factor as the participant’s status may change during the
course of followup. Availability of these time-dependent data
is limited for many of the subjects in this sample; the study
protocol did not call for annual assessment of health history
until the implementation of the UDS in 2005.
All forms of MCI, and dementia as well, reflect a hetero-
geneous (and not completely understood) group of diseases
including AD, hippocampal sclerosis, dementia with Lewy
bodies, and vascular dementia [34, 48]. This heterogeneity
may help explain the lack of significant predictors, other
than baseline hypertension, from MCICC to dementia. We
currently lack sufficient sample size to study these dementias
as separate entities, but we have recently initiated work
that will facilitate future research on which factors influence
transitions into dementia subtypes. Similarly, MCICC is
treated as a single entity here despite its well-documented
heterogeneity [49] because we lack sufficient sample size to
study the individual subtypes, and it is quite possible that
risk factors for transitions to each subtype are different.
Limitations of the current study include that the final
outcome for many of the included subjects is unknown as
they continue to be followed longitudinally. Additional fol-
lowup may change the results observed here, though they
have face validity. The generalizability of the results is also
somewhat limited due to the sample’s demographic and
geographic homogeneity, which would not be replicated in
a population-based sample, and the nature of the longitu-
dinal study, which requires brain donation at death. The
volunteers are highly motivated and highly educated, and the
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frequency of both family history of dementia and APOE-
4 is higher than what would be observed in the general
population. Biomarker data (i.e., blood, cerebrospinal fluid,
and neuroimaging) are for the most part unavailable on
these subjects, and studies that have investigated risk factors
for transition from clinical MCI to dementia have largely
been focused on biomarkers [50, 51]. Obtaining biomarkers
is extremely expensive, however, and it has been reported
that longitudinal neuropsychological testing data provides
as good or better accuracy in predicting which clinical MCI
cases will convert versus remaining stable [52]. Nevertheless,
the recently published criteria for the diagnosis of MCI due
to AD make extensive use of biomarker data [24], and this
modeling technique will allow us to incorporate these data as
they become available in the future.
Finally, a large portion of this University of Kentucky-
based longitudinal cohort was not included in this study
(n = 476). The decision to exclude all subjects not in the
original study [22] was due to the fact that the model’s
power to detect risks is based on the number of events
in the sample, not the number of subjects. The excluded
subjects, who are relatively recent recruits with about four
assessments on average, are unable to contribute events due
to this abbreviated followup. Potential differences between
included and excluded participants were assessed using
standard parametric two-group comparisons. Included and
excluded subjects compare favorably on distribution of sex,
family history, APOE-4, history of hypertension at baseline,
and time between assessments (data not shown). Although
the excluded subjects were slightly older at baseline, the effect
size is small (Cohen’s d = −0.05). Excluded subjects also
have lower education (χ2 = 8.8, 2 df, P = 0.01). That the
excluded subjects are slightly older and less educated reflects
that recruitment goals were changed in 2005 in order to
enroll older participants with lower education, and all of the
included subjects in the present model were recruited prior
to 2005.
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